[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Charles University, Czech Republic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":729},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,50,86,118,147,170,196,222,254,286,307,333,365,398,438,466,491,513,545,568,593,622,652,672,699],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645217","midwife-led-childbirth-review-and-psychological-outcomes-in-new-parents-100645217",false,"NCT07678801","Midwife-led Childbirth Review and Psychological Outcomes in New Parents","Effects of a Midwife-led Childbirth Review on Psychological Outcomes in New Parents","CROWN","Inclusion Criteria:\n\nPregnant women: Age ≥ 18 years; Singleton pregnancy; Fluency in Czech; Women can enter the study without a partner; Live birth after enrollment. Partners: Partner of an enrolled woman; Age ≥ 18 years; Planning on being present at childbirth; Fluency in Czech\n\nExclusion Criteria:\n\nPregnant women: Age \\\u003C 18 years; Multi-fetal pregnancy; Not being able to read and speak fluent Czech; A severe medical condition including significant pregnancy complications preventing participation in the intervention or assessments; Stillbirth or neonatal death; Infant admitted to intensive care for a prolonged or life-threatening condition; Acute psychiatric condition (suicidality, psychosis, manic episode, substance abuse). Partners: Age \\\u003C 18 years; Not being able to read and speak fluent Czech; Not planning on being present at childbirth \u002F after recruitment: not present at childbirth; A severe medical condition preventing participation in the intervention or assessments; Stillbirth or neonatal death; Infant admitted to intensive care for a prolonged or life-threatening condition; Acute psychiatric condition (suicidality, psychosis, manic episode, substance abuse)","ALL","18 Years",{"count":21,"type":22},1300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this clinical trial is to support psychological well-being and facilitate adjustment to parenthood among postpartum mothers and fathers through a midwife-led childbirth review (MLCR). MLCR is a structured 45-60-minute postpartum intervention focused on processing and integration of the individual's childbirth experience, involving active listening, emotional support, and provision of information. In this study, the investigators will employ the MLCR intervention developed by Gamble and Creedy (2009) for women with traumatic birth experiences, adapted for use in the general population of new parents, including both mothers and fathers\u002Fpartners. This study will compare the effectiveness of three MLCR models - MLCR provided within the first postpartum week, MLCR provided at 6-8 weeks postpartum, and MLCR provided at both time points - with standard postpartum care and with each other.",[28,29,30],"Postpartum Depression (PPD)","Perinatal Anxiety","Postpartum Mental Health",[32,33,34,35,36],"Postpartum debriefing","Perinatal mental health","Midwife-led childbirth review","Parenting","Postpartum adjustment","NOT_YET_RECRUITING","2026-06-25",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":22},"2026-07-06",{"date":45,"type":22},"2028-07-15",{"name":47,"class":48},"Charles University, Czech Republic","OTHER",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100644082","comprehensive-rehabilitation-programme-in-people-with-multiple-sclerosis-the-reconnect-ms-study-100644082","NCT07666958","Comprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS Study","Effect of Specialised Physiotherapy and Supportive Psychotherapy on Clinical Status, Neuroplasticity, and Quality of Life in People With Multiple Sclerosis: A Prospective Interventional Study With a Self-Controlled Design","RECONNECT-MS","Inclusion Criteria:\n\n* Unambiguous clinical diagnosis of multiple sclerosis (any subtype, including relapsing-remitting, secondary progressive, and primary progressive)\n* Age 18-65 years\n* Predominantly motor disability with Expanded Disability Status Scale (EDSS) 2-6\n* No relapse within the past month\n* Able to attend outpatient physiotherapy regularly and motivated to participate in the programme\n* Able and willing to complete 3 sets of clinical examinations and 3 MRI examinations\n\nExclusion Criteria:\n\n* Conditions impairing mobility (e.g., severe injuries, orthopaedic problems, other neurological conditions)\n* Acute inflammatory conditions or infections at the time of programme initiation that could affect the results or safety of the participant\n* Change or planned change of treatment (including disease-modifying therapy or corticosteroid therapy) within the past month or during the programme\n* Contraindications to MRI examination (e.g., first-trimester pregnancy, presence of a pacemaker, defibrillator, older metallic joint replacements, or other metallic implants)\n* Long-term planned absence during the programme (e.g., holiday, surgical procedure)","65 Years",{"count":60,"type":22},45,[25],"The goal of this clinical trial is to learn if a comprehensive rehabilitation programme can improve physical function, reduce fatigue, and raise quality of life in adults aged 18-65 with multiple sclerosis (MS). The study will also look at whether the programme leads to changes in brain function using magnetic resonance imaging (MRI). The main questions it aims to answer are:\n\n* Does the programme lower the overall impact of MS on daily life?\n* Does the programme improve walking, balance, and hand function?\n* Does the programme reduce the impact of fatigue?\n* Are there changes in brain connections after the programme?\n\nEach participant serves as their own comparison. They are tested 3 times: 2 months before the programme starts (T0), right before it starts (T1), and after 2 months of intensive treatment (T2). The period between T0 and T1, when no treatment is given, shows each person's natural changes over time.\n\nParticipants will:\n\n* Attend individual physiotherapy twice a week for 2 months, then 3 follow-up sessions over the next month\n* Take part in 3 group movement-awareness sessions\n* Take part in 3 group psychotherapy sessions focused on stress management and relaxation\n* Receive written nutritional guidance for autoimmune conditions\n\nTests include physical assessments, questionnaires about fatigue and quality of life, tremor measurement, and brain MRI scans.\n\nThe results may help improve rehabilitation care for people with MS and support their ability to stay active in everyday and working life.",[64],"Multiple Sclerosis",[64,66,67,68,69,70,71,72,73,74,75,76,77],"Rehabilitation","Physiotherapy","Psychotherapy","Neuroplasticity","Functional Magnetic Resonance Imaging","Quality of Life","Fatigue","Self-Controlled Design","Comprehensive Care","Motor Programme Activating Therapy","Physical Therapy Modalities","Neurological Rehabilitation","2026-06-19",{"date":80,"type":41},"2026-06-24",{"date":40,"type":22},{"date":83,"type":22},"2028-06-30",{"name":47,"class":48},1,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":18,"minAge":19,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":85},"100641040","conservative-vs-interventional-management-of-postsurgical-csf-pseudomeningocele-100641040","NCT07614399","Conservative vs Interventional Management of Postsurgical CSF Pseudomeningocele","Conservative Versus Interventional Management of Postsurgical CSF Pseudomeningocele: A Randomized Controlled Trial","PSEUDO","Inclusion Criteria:\n\n* Pseudomeningocele after elective intracranial surgery\n* Willing and able to give informed consent\n* No prior cranial or spinal surgical intervention\n* Pseudomeningocele Palpation Scale (PPS) II-IV, no severe pain of the PMC (VAS 7-10) - Tension MK\n\nExclusion Criteria:\n\n* PMC following emergency or trauma surgery\n* Known or suspected infection at the PMC site at recruitment\n* Severe comorbidities preventing participation (e.g. terminal illness, organ failure)\n* Conditions requiring urgent unrelated surgical intervention",true,"80 Years",{"count":97,"type":22},60,[25],"Dear Sir or Madam,\n\nYou have been invited to participate in a clinical study whose aim is to compare the effectiveness of two different approaches to the treatment of cerebrospinal fluid (CSF) pseudomeningocele - conservative management and interventional treatment (surgical or drainage procedures). CSF pseudomeningocele is a complication that may occur after brain surgery and is characterized by an accumulation of cerebrospinal fluid beneath the skin. At present, there is no clear consensus regarding the optimal treatment approach.\n\nHow the study will be conducted\n\nAfter enrollment in the study, you will be randomly assigned (by chance) to one of two groups:\n\nConservative management: no surgical intervention, regular follow-up, and wound care.\n\nInterventional treatment: simple aspiration\u002Fpuncture, insertion of a lumbar drain, or reoperation.\n\nDuring the study, you will be followed for a period of 1 year. Follow-up examinations will include clinical assessment and brain imaging (CT or MRI) at 4 months and 12 months after enrollment.\n\nRisks associated with the interventional group Simple cyst aspiration\u002Fpuncture: infection, bleeding into the pseudomeningocele.\n\nLumbar drainage: infection, meningitis, bleeding at the insertion site, cerebrospinal fluid leakage, nerve root irritation, headaches.\n\nReoperation: bleeding, infection, complications related to general anesthesia. Expected duration of participation in the study\n\n12 months\n\nExpected total number of participants enrolled in the study\n\n20 participants\n\nBenefit of the study\n\nThe aim of the study is to compare the effect of surgical intervention with conservative management.\n\nCompensation for participation\n\nParticipation in this study is not associated with any financial compensation.",[101,102,103,104],"CSF Leak","CSF Pressure Increased","CSF Circulation Disorder","Puncture",[106,107,108],"Cerebrospinal Fluid Leak","Postoperative Complications","Neurosurgery","RECRUITING","2026-05-22",{"date":112,"type":41},"2026-05-29",{"date":114,"type":41},"2025-11-01",{"date":116,"type":22},"2030-11-01",{"name":47,"class":48},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":85},"100612161","evaluation-of-sacovlm-video-laryngeal-mask-for-airway-management-in-military-medics-100612161","NCT07249983","Evaluation of SaCoVLM™ Video Laryngeal Mask for Airway Management in Military Medics","Evaluation of SaCoVLM™ Video Laryngeal Mask Airway for Airway Management by Inexperienced Military Medics: A Two-Phase Feasibility Study","SAVER","Inclusion Criteria:\n\n* Elective surgery\n* ASA I-II\n* need for airway management\n\nExclusion Criteria:\n\n* Pregnancy\n* known airway abnormalities\n* allergy to anesthetics",{"count":127,"type":22},50,[25],"A prospective, two-phase interventional study evaluating the performance, safety, and usability of the SaCoVLM™ video laryngeal mask airway for airway management by military medics with limited intubation experience. The study includes simulation-based training and clinical application in sedated patients undergoing elective surgery.",[131,132,133],"Airway Management","Tracheal Intubation","Anesthesia",[135,136,137,138],"SaCoVLM™","Video Laryngeal Mask","Military Medic Training","Emergency Airway","2026-04-17",{"date":141,"type":41},"2026-04-21",{"date":143,"type":41},"2026-03-01",{"date":145,"type":22},"2027-01",{"name":47,"class":48},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":94,"sex":18,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100633320","development-of-a-certified-testing-procedure-for-hip-and-groin-injuries-in-athletes-100633320","NCT07525154","Development of a Certified Testing Procedure for Hip and Groin Injuries in Athletes","Development Of A Certified Testing Procedure For Hip And Groin Injuries In Athletes","Inclusion Criteria:\n\n* Male or female competitive team sports.\n* Registered members of participating team sports.\n* Age 14 to 20 years.\n* Participation in regular team training and competition during the study period.\n* Medically cleared for full participation in training and match play at study entry.\n* Willing and able to complete preseason testing and the assigned intervention program.\n* Provided written informed consent. For participants younger than 18 years, parent or legal guardian consent will also be obtained.\n\nExclusion Criteria:\n\n* Current hip or groin injury causing time loss or restricting full participation in training or competition at baseline.\n* Lower extremity or lumbar spine injury at baseline that limits safe participation in testing or intervention exercises.\n* Surgery involving the hip, groin, pelvis, lumbar spine, or lower extremity within the previous 6 months.\n* Any neurological, musculoskeletal, cardiovascular, or other medical condition that would contraindicate participation in the intervention or testing procedures.\n* Inability to complete baseline assessments.\n* Planned absence during a substantial part of the preseason intervention period or competitive season.\n* Noncompliance with study procedures or refusal to provide consent.","14 Years","20 Years",{"count":157,"type":22},170,[25],"Hip and groin injuries affect approximately 21% of professional athletes annually, causing significant time loss. As roughly 48% of these cases result from non-contact mechanisms, they are potentially preventable through optimized diagnostic screening. Evidence strongly links restricted hip range of motion (ROM) and strength deficits to an increased injury risk. This project aims to (1) develop a rigorously validated diagnostic testing procedure by comparing different joint positions, movement velocities, and muscle contractions to establish a preventive \"gold standard\" screening battery. dditionally, (2) pilot targeted prevention interventions over a competitive season. Using a crossover design, the research evaluates three protocols: Strength-focused,Flexibility-focused:and control group. (3) Implement of a Centralized Injury Reporting System. Combining comprehensive diagnostic screening with these practical interventions will yield a powerful tool for clinicians and coaches to effectively reduce the incidence and burden of non-contact hip and groin injuries",[161],"Hip Injury","2026-04-06",{"date":164,"type":41},"2026-04-13",{"date":166,"type":22},"2027-01-01",{"date":168,"type":22},"2031-12-31",{"name":47,"class":48},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":94,"sex":18,"minAge":177,"maxAge":154,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":85},"100632352","feasibility-and-preliminary-effects-of-a-structured-resistance-training-program-in-children-aged-10-14-years-100632352","NCT07512570","Feasibility and Preliminary Effects of a Structured Resistance Training Program in Children Aged 10-14 Years","Feasibility and Preliminary Effects of a Structured Resistance Training Programme in Children Aged 10-14 Years: A Randomised Controlled Pilot Study","Inclusion Criteria:\n\n* Children aged 10-14 years\n* Ability to safely participate in supervised resistance training\n* Written informed consent from a parent or legal guardian\n* Assent provided by the child participant\n* Willingness to comply with all study procedures and attend training sessions\n\nExclusion Criteria:\n\n* Acute illness at the time of enrolment\n* Recent musculoskeletal injury or immobilisation\n* Chronic cardiovascular, metabolic, or endocrine disorders\n* Use of medications that may affect muscle composition or function\n* Any medical or psychological condition that may compromise safety or adherence","10 Years",{"count":179,"type":22},31,[25],"This study is a randomised controlled pilot trial designed to evaluate the feasibility, safety, and preliminary efficacy of a 12-week resistance training intervention in children aged 10-14 years. The study adheres to the CONSORT extension for randomised pilot and feasibility trials and incorporates key elements of the SPIRIT guidelines for clinical trial protocols.\n\nThe primary purpose of the study is to assess feasibility-related outcomes and to generate effect size estimates to inform the design of a subsequent fully powered randomised controlled trial (RCT).",[183,184],"Muscle Architecture","Ultrasonic Diagnosis",[186,187,188],"Resistance Training","Children","Feasibility Study","2026-04-01",{"date":162,"type":41},{"date":192,"type":22},"2026-09-01",{"date":194,"type":22},"2028-09-30",{"name":47,"class":48},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":221,"locationsCount":85},"100631369","pilot-verification-of-the-usability-of-automatic-evaluation-of-the-box-and-block-test-by-a-computer-program-in-occupational-therapy-practice-100631369","NCT07499778","Pilot Verification of the Usability of Automatic Evaluation of the Box and Block Test by a Computer Program in Occupational Therapy Practice","Inclusion Criteria:\n\n* a client of a selected nursing home who is willing to be tested at the time of data collection\n* age 65 and over\n* signature of informed consent\n\nExclusion Criteria:\n\n* severe cognitive, visual or motor limitations preventing completion of the entire test\n* failure to complete the entire test",{"count":203,"type":22},40,"OBSERVATIONAL","The aim of the project is to verify the usability of a computer program for automatic evaluation of the Box and Block Test performed by seniors aged 65 and over and to determine whether it is more advantageous to use it in clinical practice compared to the usual manual evaluation of the Box and Block Test by an occupational therapist.",[207],"Seniors",[209,210,211,212,213,214],"seniors","dexterity","Box and Block Test","computer program","occupational therapy","assessment","2026-03-24",{"date":217,"type":41},"2026-03-30",{"date":189,"type":22},{"date":220,"type":22},"2027-09-30",{"name":47,"class":48},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":229,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100485528","study-comparing-transobturator-cystocele-vs-anterior-vaginal-repairs-100485528","NCT05602246","Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS","STARS","Inclusion Criteria:\n\n* (at least) 2nd stage prolapse of the anterior compartment (Ba ≥ -1)\n* Age ≥ 50 years\n* Symptom bulge\n* Ability to speak Czech or English\n\nExclusion Criteria:\n\n* Malignancy","FEMALE","50 Years",{"count":232,"type":22},592,[25],"Surgical correction of the prolapse in the anterior compartment remains one of the major challenges in urogynecology. Paravaginal defect in level II of vaginal fixation results in the majority of cystoceles. Clinically, these defects are often combined and\u002For may be bilateral. Hence, careful assessment and individualized planning of the surgical procedure is essential to optimize cystocele repair outcome. Several surgical techniques and approaches have been used for cystocele repair. After the ban on transvaginal meshes, the interest in native tissue repair has risen. Paravaginal defect repair is an effective surgery for paravaginal defect reconstruction. There is a current trend to utilize transvaginal surgery instead of more invasive transabdominal surgery. A novel method of transvaginal paravaginal defect repair - TOCR (transobturator cystocele repair) was suggested. The principle objective of the present trial is to compare its efficacy and safety to preexisting method of native tissue cystocele repair.",[236,237,238],"Pelvic Organ Prolapse","Cystocele","Cystocele and Incomplete Uterovaginal Prolapse",[240,241,242,243,244],"Pelvic organ prolapse","Quality of life","TOCR","Anterior vaginal wall repair","Transobturator cystocele repair","2026-03-18",{"date":247,"type":41},"2026-03-19",{"date":249,"type":41},"2022-12-01",{"date":251,"type":22},"2034-11-01",{"name":47,"class":48},8,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":229,"minAge":19,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":267,"conditions":268,"keywords":274,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":85},"100423118","phase-3-prehabilitation-in-gynaecological-cancer-patients-100423118","NCT04789694","Prehabilitation in Gynaecological Cancer Patients","Prehabilitation in Patients With Gynaecological Cancer Planned for Postponed Surgical Management: A Prospective Randomised Trial.","PHOCUS","Inclusion criteria\n\nTwo groups of patients will be eligible for the trial:\n\ni) Epithelial ovarian cancer patients referred for NACT: a) FIGO stage III or IV disease; b) Patient is not a candidate for primary debulking surgery; c) Patient is a suitable candidate for standard of care combined chemotherapy; d) Patient is a candidate for interval.debulking surgery\n\nii) Stage I or II endometrial cancer patients classifying as frail according to the validated modified Frailty Index: a) FIGO stage I or II; b) Patient is classified as frail; c) Patient is suitable candidate for hormonal therapy.\n\nExclusion criteria\n\n1. Second malignant tumour (under the treatment)\n2. Patient is not suitable for any surgery delay\n3. Patient is not physically able to meet the prehabilitation intervention plan or is unable to walk","85 Years",{"count":264,"type":22},64,[266],"PHASE3","Prehabilitation refers to interventions aiming to improve patients' resilience and functional capacity before a known stressful event, e.g., scheduled surgery. These interventions usually consist of physical activity and psychological and nutritional support. There is substantial evidence of the positive effect of multimodal prehabilitation among patients treated surgically for non-gynaecological cancers; however, no prospective data are available in gynaecological cancer patients.\n\nPHOCUS trial is a prospective randomised trial aiming to evaluate the role of multimodal prehabilitation in patients with gynaecological cancer. Sixty-four patients will be randomised in single institution within 36 months with a 1:1 ratio into ARM A: control arm which will be provided with a basic information and standard of care support; ARM B: active arm undergoing multimodal prehabilitation composed of physical activity and psychological and nutritional support. All patients will be assessed at standard intervals (three times during the trial) by a spectrum of non-invasive tests, evaluating physical functional capacity, postoperative morbidity, nutritional status, level of stress and anxiety, and quality of life.",[269,270,271,272,273],"Ovarian Cancer","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Endometrial Cancer","Frailty",[275,276,277,241,278,273,279],"Prehabilitation","Epitelial ovarian cancer","Functional capacity","Multimodal prehabilitation","Endometrial cancer",{"date":247,"type":41},{"date":282,"type":41},"2021-01-25",{"date":284,"type":22},"2026-06-30",{"name":47,"class":48},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":85},"100626698","la-function-after-pfa-in-paroxysmal-af-100626698","NCT07439016","LA Function After PFA in Paroxysmal AF","Acute Impairment in Left Atrial and Left Atrial Appendage Function Pre- and Post-Pulse Field Ablation Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Prospective Intraprocedural Intracardiac Echocardiography Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Paroxysmal AF in sinus rhythm at procedural onset\n\nExclusion Criteria:\n\n* Persistent or long-standing AF\n* Prior atrial ablation\n* Significant valvular disease\n* A history of LAA closure",{"count":127,"type":22},"A prospective study that investigates the changes in LA echocardiographic parameters after PFA for paroxysmal AF.",[296],"Atrial Fibrillation (AF)",[298,299,300],"atrial fibrillation","catheter ablation","LA function","2026-03-17",{"date":245,"type":41},{"date":114,"type":41},{"date":305,"type":22},"2026-11-01",{"name":47,"class":48},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":94,"sex":229,"minAge":19,"maxAge":230,"enrollmentInfo":315,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":85},"100616710","single-center-evaluation-of-human-milk-quantity-and-quality-over-five-years-100616710","NCT07309146","Single-center Evaluation of Human Milk Quantity and Quality Over Five Years","Evaluation of the Quantity and Quality of Human Breast Milk Collected in a Single-center Milk Bank Over the Last Five Years","HUMBLE","Inclusion Criteria:\n\n* Lactating women who donated human milk to the hospital-based human milk bank at České Budějovice Hospital during the period 2021-2025.\n* Accepted as donors according to local eligibility criteria for human milk donation.\n* At least one recorded donation of human milk with available data on donation date and volume in the milk bank database.\n* Availability of basic maternal and perinatal data (e.g., age, BMI, parity, mode of delivery, timing of donation) in the hospital information sys-tem.\n\nExclusion Criteria:\n\n* Donors with no recorded volume or date of human milk donation in the milk bank database.\n* Records with evident data errors or inconsistencies that cannot be reliably corrected (e.g., implausible dates or volumes).",{"count":316,"type":22},500,"This single-center retrospective observational study includes all human milk donors collaborating with the milk bank at České Budějovice Hospital between 2021 and 2025. Using anonymized data extracted from the hospital database, the study will quantify the frequency of donations and the individual and cumulative volume of donated human milk and will assess the impact of key maternal and perinatal factors - including age, BMI, parity, mode of delivery, and timing of donations - on the quantity and quality of donated milk, based on routine biochemical and microbiological parameters.",[319],"Lactating Women - Human Milk Donors",[321,322,323,324,325],"donor human milk","human milk bank","milk donation","milk volume","milk quality","2026-03-16",{"date":245,"type":41},{"date":329,"type":41},"2026-01-01",{"date":331,"type":22},"2026-09-30",{"name":47,"class":48},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":341,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":85},"100629500","exercise-based-strategies-for-chronic-back-pain-100629500","NCT07475481","Exercise-Based Strategies for Chronic Back Pain","Innovative Exercise-Based Strategies for Managing Chronic Back Pain: A Multisystem Health Approach","BACK-FIT","Inclusion Criteria:\n\n* Chronic low back pain lasting more than 12 weeks, with current low back pain at screening\u002Fbaseline.\n* Resting blood pressure below 139\u002F89 mmHg.\n* Health status allowing participation in moderate-intensity resistance training and aerobic activity.\n* Physically active, but not professional athletes.\n* Non-smoker.\n* Able and willing to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Absolute or relative contraindications to resistance training or other clinically relevant cardiovascular contraindications.\n* Coronary artery disease, heart rhythm disorders, acute myocarditis, Marfan syndrome, or other cardiovascular conditions judged unsafe by the study physician.\n* History of myocardial infarction, cerebrovascular disease, peripheral vascular disease, or grade II-IV hypertension.\n* Type 1 or type 2 diabetes mellitus.\n* Severe obesity (BMI \\>= 40.0 kg\u002Fm2).\n* Infectious disease at screening (for example, COVID-19 or influenza).\n* Current treatment for chronic low back pain from another healthcare provider.\n* Prior spine surgery or lower-limb surgery.\n* Structural spinal deformity such as spondylolisthesis or spondylolysis.\n* Spinal fracture, inflammatory spinal disorder, or neurological signs of nerve root compromise, including decreased tendon reflexes, sensory loss, or motor deficits.\n* Dizziness during exercise.\n* Use of medications other than analgesics and non-steroidal anti-inflammatory drugs, unless specifically approved by the study physician.","40 Years","60 Years",{"count":344,"type":22},120,[25],"This randomized, controlled, five-arm, parallel-group trial will evaluate the effects of 8 weeks of supervised resistance training and developmental position-based exercise, with or without real-time non-invasive intra-abdominal pressure biofeedback, in adults aged 40 to 60 years with chronic low back pain. The trial will compare supervised gym-based agonist-antagonist paired set resistance training with OHMTRACK, supervised gym-based resistance training without OHMTRACK, supervised physiotherapy-based developmental exercise with OHMTRACK, home-based developmental exercise with OHMTRACK, and an active control condition. Primary outcomes will assess changes in pain and physical function after the intervention. Secondary outcomes will include neuromuscular coordination, postural stabilization, cardiovascular, respiratory, metabolic, behavioral, feasibility, and follow-up outcomes.",[348],"Chronic Low-back Pain (cLBP)",[350,351,352,353,354,355,356,357],"chronic low back pain","resistance training","exercise therapy","dynamic neuromuscular stabilization","developmental positions","intra-abdominal pressure","rehabilitation","postural stabilization","2026-03-11",{"date":326,"type":41},{"date":361,"type":22},"2027-07-01",{"date":363,"type":22},"2030-03-31",{"name":47,"class":48},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":94,"sex":18,"minAge":19,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":386,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":85},"100628951","multimodal-therapy-for-somatosensory-tinnitus-100628951","NCT07468318","Multimodal Therapy for Somatosensory Tinnitus","Multimodal Therapeutic Approach to Tinnitus Treatment With Focus on Somatosensory Components: A Randomised Controlled Trial Integrating Physiotherapy, Structured Exercise Program, and Psychological Intervention","SOMATIN","Inclusion Criteria:\n\n* Age 18-70 years (inclusive)\n* Chronic subjective tinnitus present for ≥6 months\n* Tinnitus Handicap Inventory (THI) score ≥18 points (indicating at least mild tinnitus handicap)\n* Positive somatosensory modulation test: ability to reproducibly modulate tinnitus (change in loudness, pitch, or quality) through at least one of the following manoeuvres:\n* Jaw movements (mouth opening, lateral excursion, protrusion, clenching)\n* Neck movements (flexion, extension, rotation, lateral flexion)\n* Pressure on specific head\u002Fneck muscles\n* Eye movements or shoulder elevation\n* Willing and able to attend all study sessions over 28 weeks\n* Adequate cognitive capacity to understand study procedures and complete questionnaires in the Czech language\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Audiological\u002FENT Exclusions:\n* Objective or pulsatile tinnitus\n* Active ear pathology requiring treatment:\n* Acute otitis media or externa\n* Chronic suppurative otitis media\n* Cholesteatoma\n* Meniere's disease with recent vertigo attacks (\\\u003C3 months)\n* Suspected retrocochlear pathology:\n* Acoustic neuroma (vestibular schwannoma)\n* Cerebellopontine angle tumor\n* Neurological Exclusions:\n* Neurological disease affecting brainstem or auditory pathways:\n* Multiple sclerosis with brainstem involvement\n* Stroke affecting auditory pathways\n* Brain tumor\n* Epilepsy or active seizure disorder\n* Musculoskeletal Exclusions:\n* Contraindications to manual therapy:\n* Severe cervical spine instability\n* Rheumatoid arthritis with atlantoaxial instability\n* Down syndrome\n* Vertebrobasilar insufficiency\n* Severe osteoporosis with fracture risk\n* Recent cervical spine surgery (\\\u003C6 months)\n* Recent head or neck trauma (\\\u003C3 months)\n* Ongoing physiotherapy or manual therapy for temporomandibular joint or cervical spine (\\\u003C3 months prior to enrollment)\n* Psychiatric Exclusions:\n* Severe psychiatric disorder:\n* Active psychosis\n* Severe depression requiring inpatient treatment\n* Acute suicidal ideation (PHQ-9 item 9 score ≥2)\n* Active substance abuse disorder\n* Other Exclusions:\n* Pregnancy (due to modifications needed in physical examination and treatment)\n* Ongoing litigation or compensation claims related to tinnitus or hearing loss\n* Current participation in another interventional clinical trial\n* Expected change of residence or long-term absence (\\>2 weeks) during the study period\n* Unable or unwilling to comply with study procedures and attend all sessions","70 Years",{"count":375,"type":22},160,[25],"Tinnitus (ringing or buzzing in the ears) affects approximately 10-15% of the adult population and significantly reduces quality of life in many patients. In a substantial proportion of cases, tinnitus is associated with dysfunction of the temporomandibular joint (TMJ) and cervical spine - this subtype is called somatosensory tinnitus.\n\nThis randomised controlled trial investigates the effectiveness of a multimodal intervention combining: (1) physiotherapy targeting TMJ and cervical spine dysfunction, (2) a structured combined exercise program (aerobic + resistance + breathing), and (3) psychological support (cognitive-behavioural psychoeducation) in patients with chronic somatosensory tinnitus.\n\nThe study also examines the acute effects of different types and intensities of physical exercise on tinnitus perception, and performs psychometric validation of Czech-language tinnitus assessment questionnaires.\n\nParticipants (N=160, aged 18-70 years) will be randomly assigned to either the multimodal intervention group (8 weeks, 5 sessions\u002Fweek) or a control group. Follow-up assessments will be conducted at 3, 12, and 24 months. The primary outcome is the change in the Tinnitus Handicap Inventory (THI) score.",[379,380,381,382,383,384,385],"Ear Noise","Tinnitus, Noise Induced","Tinnitus, Subjective","Headache Other","Temporomandibular Dysfunction","Cervical Migraine Syndrome","Chronic Tinnitus",[352,387,388,389,390,391],"tinnitus","multimodal therapy","subjective noise","somatosensory tinnitus","physiotherapy",{"date":393,"type":41},"2026-03-12",{"date":166,"type":22},{"date":396,"type":22},"2030-12-31",{"name":47,"class":48},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":94,"sex":229,"minAge":19,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":408,"conditions":409,"keywords":415,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":437,"locationsCount":85},"100628488","menstrual-cycle-and-womens-performance-100628488","NCT07462286","Menstrual Cycle and Women's Performance","The Relationship Between the Menstrual Cycle and Physical Performance in Women","Inclusion Criteria:\n\n* Female, age 18-35 years\n\nPremenopausal\n\nOccasional to recreational level of physical activity\n\nWilling and able to track menstrual cycle using a mobile application for approximately 2 months\n\nWilling and able to attend 3 laboratory visits scheduled to predefined menstrual cycle phases\n\nAble to provide written informed consent\n\nExclusion Criteria:\n\n* Irregular menstrual cycle (outside protocol-defined regularity)\n\nCurrent pregnancy\n\nUse of hormonal medication for therapeutic purposes (per protocol)\n\nCurrent acute illness at time of testing\n\nMusculoskeletal injury of the lower limb limiting safe performance testing\n\nContraindication to body composition assessment methods used in the study (e.g., BIA\u002FDXA, per site protocol)\n\nAny other condition that, in the investigator's judgment, may interfere with safe participation or data quality","35 Years",{"count":407,"type":22},32,"This study examines how different phases of the menstrual cycle are associated with selected performance and musculoskeletal parameters in physically active women aged 18-35 years.\n\nParticipants will track their menstrual cycle using a mobile app for approximately 2 months and attend 3 laboratory visits scheduled to specific cycle phases.\n\nAt each visit, participants will complete non-invasive assessments including lower-limb strength\u002Fperformance testing, musculoskeletal measurements (muscle and tendon properties), body composition assessment, and symptom-related questionnaires.\n\nThe goal is to improve understanding of physiological variability across the menstrual cycle and support evidence-based planning of training, testing, and clinical practice in women.",[410,411,412,413,414],"Menstrual Cycle","Physical Performance","Muscle Strength","Musculoskeletal System","Healthy Volunteers",[416,417,418,419,420,421,422,423,424,425,426,427,428,429,430],"menstrual cycle phase","follicular phase","luteal phase","female athletes","physically active women","neuromuscular performance","lower limb strength","muscle mechanical properties","tendon mechanical properties","body composition","symptom tracking","cycle tracking app","repeated measures","observational study","women's health","2026-03-05",{"date":433,"type":41},"2026-03-10",{"date":189,"type":22},{"date":436,"type":22},"2027-03-30",{"name":47,"class":48},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":454,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":85},"100626420","reduction-of-muscle-catabolism-through-brain-activation-in-burn-patients-100626420","NCT07435402","Reduction of Muscle Catabolism Through Brain Activation in Burn Patients","Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (REMBRANT)","REMBRANT","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Severe burn injury involving more than 30% of total body surface area (TBSA)\n* Admission to the intensive care unit\n* Expected need for invasive mechanical ventilation and continuous sedation for at least 7 days\n* Ability to obtain written informed consent from the patient or a legally authorized representative\n\nExclusion Criteria:\n\n* Pre-existing severe neuromuscular or neurodegenerative disease\n* Known contraindication to inhalational sedation with isoflurane\n* Pregnancy or breastfeeding\n* Participation in another interventional clinical trial that could interfere with the study outcomes\n* Any condition that, in the opinion of the investigator, would make participation in the study unsafe or interfere with protocol adherence",{"count":447,"type":22},30,[25],"Patients with extensive burn injuries frequently develop severe skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy. This condition delays ventilator weaning, prolongs intensive care unit (ICU) and hospital stay, and contributes to long-term functional impairment and reduced quality of life. In burn patients, muscle loss is particularly pronounced during the early post-injury phase and is associated with mitochondrial dysfunction and altered neuromuscular signaling.\n\nEffective strategies to prevent muscle catabolism in critically ill burn patients remain limited. Although early active rehabilitation is beneficial, many patients are unable to participate due to deep sedation, mechanical ventilation, or clinical instability. Therefore, innovative rehabilitation approaches applicable during the acute phase of critical illness are needed.\n\nThe REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial evaluating whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle loss in adult patients with severe burns. Thirty patients with burns involving more than 30% of total body surface area who require invasive mechanical ventilation and prolonged sedation will be randomized in a 1:1 ratio to standard care or an intervention group.\n\nBoth groups will receive standardized burn treatment and conventional rehabilitation. The intervention group will additionally receive the Burn-Bundle Extended Rehabilitation Program, combining inhalational isoflurane sedation with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when clinically feasible.\n\nThe primary outcome is change in skeletal muscle mass and strength. Secondary outcomes include ICU length of stay, ventilator-free days, mitochondrial function, and health-related quality of life.",[451,452,453],"Burns - Multiple","Critical Illness","Muscle Weakness",[455,456,457],"extensive burn injury","skeletal muscle wasting","brain activation","2026-02-21",{"date":460,"type":41},"2026-02-27",{"date":462,"type":22},"2026-05-01",{"date":464,"type":22},"2030-06-30",{"name":47,"class":48},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":95,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":4},"100625568","extended-ablation-versus-pulmonary-vein-isolation-to-treat-persistent-atrial-fibrillation-100625568","NCT07424326","Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation","EXTEND-PVI","Inclusion Criteria:\n\n* symptomatic persistent AF\n* ≥1 episode of persistent AF in the last 12 months\n* signed informed consent\n\nExclusion Criteria:\n\n* first-manifested AF, paroxysmal AF, long-standing persistent AF, permanent AF\n* SR on admission without Class I\u002FIII AADs\n* AF of secondary cause (e.g. hyperthyroidism)\n* any previous LA ablation\n* severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention\n* left ventricular ejection fraction ≤40%\n* pulmonary hypertension (estimated systolic pulmonary artery pressure ≥40 mm Hg)\n* symptomatic coronary artery disease\n* pregnancy\n* LA anteroposterior diameter ≥55 mm\n* body mass index ≥40 kg\u002Fm2\n* age ≥80 years\n* chronic kidney disease stage 3b or higher\n* contraindication to anticoagulation\n* general contraindications of catheter ablation\n* life expectancy \\\u003C2 years due to other comorbidities",{"count":474,"type":22},450,[25],"The aim is to determine the effect of extended ablation (pre-specified linear PF\u002FRF lesion set) in addition to PVI in symptomatic persistent AF patients on AF\u002FAT\u002FAFL recurrence. The study is designed as multicenter, randomized trial. Eligible patients are patients with persistent AF (but not long-standing persistent AF) planned for a first-ever AF ablation procedure. Patients will be randomly assigned 1:1 either to: i) PVI-only, or ii) PVI-plus arms. Patients in both groups will undergo catheter ablation using an ablation system capable of performing PF and RF ablation (Sphere-9, Affera, Medtronic). Patients randomized to the PVI-only arm will undergo only PVI. Patients randomized to the PVI-plus arm will undergo PVI plus linear lesions (roof, bottom line, lateral or anterior MI line, and septal line in the LA; intercaval line and cavotricuspid line in the RA). The primary endpoint will be freedom from recurrent AF\u002FAT\u002FAFL, assessed as time-to-first recurrence in the period of 12 months after randomization (post 2-month blanking period). Secondary clinical endpoints will be 1) 12-month differences in AF\u002FAT\u002FAFL burden, 2) AF\u002FAFL\u002FAT-related outcomes (hospitalization or emergency visits), 3) Quality of life according to the AFEQT questionnaire score at 12 months, 4) MACE defined as cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failure. Secondary endpoints will be evaluated throughout the entire (minimum 12-month) follow-up period.",[296],[479,299,480,481,482],"persistent atrial fibrillation","pulmonary vein isolation","pulsed-field ablation","radiofrequency ablation","2026-02-14",{"date":485,"type":41},"2026-02-20",{"date":487,"type":22},"2026-06-01",{"date":489,"type":22},"2029-12-31",{"name":47,"class":48},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":85},"100617857","electroconvulsive-therapy-augmented-with-transcranial-magnetic-stimulation-for-treatment-resistant-depression-100617857","NCT07324070","Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression","New Methods Electroconvulsive Therapy Augmentation","RMTSECT2","Inclusion Criteria:\n\n* Age equal to 18 or higher\n* MADRS (Montgomery-Asberg Depression Scale) qual or higher than 20\n* Major depressive disorder according to ICD 10\n\nExclusion Criteria:\n\n* Other axis 1 disorder (for example schizofrenia, addiction, etc.)\n* No dementia\n* ECT in the last 3 months\n* TMS in the last 3 months\n* Psychotic disease or symptoms\n* Ppregnancy or lactation\n* Any neurological disease (for example epilepsy, etc.)\n* Participation in another clinical trial within the last 30 days\n* somatic condition which contraindicates ECT",{"count":127,"type":22},[25],"The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energy",[503,504],"Major Depressive Disorder (MDD)","Treatment Resistant Depression (TRD)","2026-01-06",{"date":507,"type":41},"2026-01-07",{"date":509,"type":41},"2026-01-05",{"date":511,"type":22},"2029-01-05",{"name":47,"class":48},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":521,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":544},"100618821","neuroproprioceptive-equine-assisted-physiotherapy-for-spinal-muscular-atrophy-100618821","NCT07336602","Neuroproprioceptive Equine-Assisted Physiotherapy for Spinal Muscular Atrophy","Immediate and Sustained Effects of Intensive Neuroproprioceptive Equine-Assisted Physiotherapy in Children With Spinal Muscular Atrophy: A Randomized Crossover Trial","NEUROEQUIP","Inclusion Criteria:\n\n* Age between 2 and 9 years\n* Clinical diagnosis of spinal muscular atrophy (SMA) type I, II, or III\n* Stable health condition for at least 6 months prior to enrollment\n* Ability to participate in the study procedures\n* Written informed consent provided by a parent or legal guardian\n\nExclusion Criteria:\n\n* Hip dislocation\n* Known allergy to horses or the stable environment\n* Severe fear of horses that would prevent participation in equine-assisted physiotherapy\n\nAny other medical condition that, in the investigator's opinion, would interfere with safe participation in the study","2 Years","9 Years",{"count":524,"type":22},20,[25],"This study investigates whether Equine-Assisted Physiotherapy based on Neuro-proprioceptive \"Facilitation and Inhibition\" (NEUROEQUIP-SMA) can improve movement, posture, breathing, and quality of life in children with spinal muscular atrophy (SMA). This therapy uses the horse's rhythmic movement together with targeted sensory and manual stimulation to trigger natural motor reactions starting from the pelvis, lower the threshold for muscle activation, and support coordinated motor patterns. The study compares this method with standard individual physiotherapy based on the same neuro-proprioceptive facilitation and inhibition principles, but performed without the horse. Twenty children aged 2 to 9 years will receive both therapies in two separate 6-day blocks, in random order (crossover design). The researchers will assess muscle fatigue, coordination, breathing function, movement quality and quantity, quality of life, and changes in selected blood biomarkers. The results may help develop better rehabilitation strategies for children with SMA who are receiving modern pharmacological or gene therapy.",[528],"Spinal Muscular Atrophy (SMA)",[530,531,532,533,534,76,535,536],"Muscular atrophy, Spinal","Genetic Therapy","Equine-Assisted Therapy","Child","Pediatrics","RNA, Long Noncoding","Neuro-proprioceptive Principles","2025-12-30",{"date":539,"type":41},"2026-01-13",{"date":541,"type":22},"2026-04-15",{"date":284,"type":22},{"name":47,"class":48},4,{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":85},"100617582","efficacy-and-safety-of-the-apgo-algorithm-for-automated-insulin-delivery-100617582","NCT07320495","Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery","Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery: The RENEW Study","Inclusion Criteria:\n\n* patients with T1D\n* type 1 diabetes for ≥1 years\n* ≥ 18 years old\n* written informed consent prior to starting study related activity\n\nExclusion Criteria:\n\n* severe noncompliance\n* lactation, pregnancy, intending to become pregnant during study\n* use of medication with effects on carbohydrate metabolism",{"count":553,"type":22},200,[25],"The Medtrum TouchCare Nano system with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic. However, until now, no prospective clinical study has evaluated its efficacy and safety under real-world conditions. The RENEW study is the first to address this topic.",[557],"Diabetes Mellitus Type 1",[559,560],"automated insulin delivery system","patch pump","2025-12-25",{"date":505,"type":41},{"date":564,"type":41},"2025-06-19",{"date":566,"type":22},"2028-06-19",{"name":47,"class":48},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":576,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":4},"100613805","external-negative-pressure-during-lisa-100613805","NCT07271368","EXTERNAL NEGATIVE PRESSURE DURING LISA","AN EXTERNAL NEGATIVE PRESSURE USE DURING THE LISA PROCEDURE. A FEASIBILITY STUDY","ENCP LISA","Inclusion Criteria:\n\n* Preterm infants ≥ 32 weeks of gestational age\n* FiO₂ \\> 0.30 for more than 30 minutes on CPAP (6 - 8 cm H₂O) or HFNC (8 l\u002Fmin)\n* Increased work of breathing despite FiO₂ \\\u003C 0.30\n* Birth weight \\> 800 g\n* X-ray confirmed RDS\n* Availability of all required devices and appropriately fitting cuirass\n\nExclusion Criteria:\n\n* Requirement for endotracheal intubation or mechanical ventilation prior to surfactant administration\n* Major congenital anomalies (cardiac, pulmonary, chromosomal)\n* Known or suspected neuromuscular or metabolic disorders\n* Lack or withdrawal of informed parental consent","1 Hour","3 Days",{"count":7,"type":22},[25],"The goal of this clinical trial is to evaluate the feasibility, safety, and preliminary effectiveness of applying external continuous negative pressure (ECNP) during less invasive surfactant administration (LISA) in preterm infants with respiratory distress syndrome (RDS). It will also assess whether ECNP can improve surfactant distribution and reduce procedural complications. The main questions it aims to answer are:\n\nDoes ECNP during LISA improve surfactant distribution and oxygenation in preterm infants with RDS?\n\nDoes ECNP reduce the occurrence of complications such as desaturation, bradycardia, or apnea during the procedure?\n\nDoes ECNP reduce the need for repeated surfactant administration?\n\nResearchers will evaluate ECNP combined with LISA in preterm infants on HFNC or CPAP to see if it improves outcomes compared to standard methods.\n\nParticipants will:\n\nReceive LISA with ECNP support via a soft thoracoabdominal cuirass\n\nBe monitored for procedural complications like desaturation, bradycardia, or apnea\n\nHave their oxygenation levels, surfactant distribution, and need for repeated surfactant doses assessed\n\nPrimary Outcome:\n\nThe procedure will be considered safe if no more than 20% of participants experience serious adverse events, such as apnea requiring positive pressure ventilation or persistent desaturation.\n\nSecondary Outcomes:\n\nCompletion of LISA without interruption due to complications\n\nReduction of FiO₂ to ≤0.25 within 3 hours post-surfactant administration\n\nAvoidance of repeated surfactant doses via the INSURE method",[582],"Neonatology",[584],"LISA, negative pressure, neonatology, preterm, surfactant","2025-12-16",{"date":587,"type":41},"2025-12-17",{"date":589,"type":22},"2025-12-22",{"date":591,"type":22},"2027-01-31",{"name":47,"class":48},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":544},"100614011","burden-of-tick-borne-encephalitis-and-cost-effectiveness-of-vaccination-in-the-czech-republic-100614011","NCT07274046","Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech Republic","Clinical and Public-Health Impact of Tick-Borne Encephalitis: A Prospective Multicenter Observational Study With 12-Month Follow-up and Cost-Effectiveness Analysis","ENCZECH","Inclusion Criteria:\n\n* Hospitalization due to suspected central nervous system (CNS) infection.\n* Laboratory-confirmed TBE, defined as:\n\nthe presence of CNS symptoms and cerebrospinal fluid pleocytosis (\\>5 × 10⁶\u002FL) and TBEV IgM and IgG seropositivity in serum, or detection of TBEV IgM in CSF in previously vaccinated individuals.\n\n* All age groups (children and adults).\n* Ability to participate in scheduled follow-up (in person or via telephone).\n* Informed consent provided by the patient or legal guardian (for minors).\n\nExclusion Criteria:\n\n* Alternative diagnosis explaining the CNS symptoms\n* Missing essential clinical or laboratory data required to confirm TBE or assess outcomes.\n* Refusal or inability to provide informed consent.\n* Inability to complete follow-up assessments, including situations where reliable contact cannot be maintained.\n* Coexisting severe neurological disorder unrelated to TBE that prevents meaningful evaluation of sequelae (e.g., advanced neurodegenerative disease, severe preexisting motor disability).",{"count":602,"type":22},209,"This observational study follows children and adults who were hospitalized with tick-borne encephalitis (TBE) in the Czech Republic. The aim is to better understand how individuals recover from TBE, which symptoms may persist after the infection, and which patients may require additional support during their recovery. Participants are examined several times after hospital discharge (at 2-4 weeks, 3 months, 6 months, and 12 months) to observe changes in symptoms, functional status, and daily activities. Follow-up assessments include evaluation of common post-infection problems such as tiredness, headaches, memory or concentration difficulties, sleep issues, or limb weakness. Symptoms lasting for several months are categorized as post-encephalitic syndrome (PES).\n\nThe study also assesses how TBE affects daily functioning, school and work performance, and overall quality of life using questionnaires and short functional assessments. In addition, the study includes a public-health component that estimates the broader impact of TBE in the population and evaluates the potential benefits of vaccination in preventing long-term health complications.\n\nThe findings aim to support improved patient care, follow-up planning, and evidence-based public-health decision-making in the Czech Republic.",[605],"Tick Borne Encephalitis (TBE)",[607,608,609,610,611,612,613],"tick-borne encephalitis","sequelae","post-encephalitic syndrome","age","TBEV","encephalitis","cost-effectiveness","2025-12-09",{"date":616,"type":41},"2025-12-10",{"date":618,"type":41},"2023-04-01",{"date":620,"type":22},"2026-12",{"name":47,"class":48},{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":629,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":632,"briefSummary":633,"conditions":634,"keywords":637,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":85},"100612059","comprehensive-therapeutic-program-for-people-with-multiple-sclerosis-100612059","NCT07248657","Comprehensive Therapeutic Program For People With Multiple Sclerosis","BIB_MS","Inclusion criteria:\n\n* Confirmed clinical diagnosis of MS\n* Age ≤ 75 years\n* Predominantly motor impairment\n* EDSS 2-8\n* Ability and motivation to attend outpatient physiotherapy regularly\n\nExclusion criteria:\n\n• Contraindications such as severe orthopedic or cardiovascular dysfunction, or presence of another neurological disorder","75 Years",{"count":631,"type":22},26,[25],"This study investigates the effectiveness of an intensive multidisciplinary rehabilitation program for people with multiple sclerosis (PwMS). The program integrates intensive outpatient physiotherapy, psychotherapeutic consultations, and nutritional counseling to enhance motor and cognitive functions, promote neuroplasticity, and improve overall well-being as well as physical performance in PwMS. Through clinical assessments and standardized questionnaires, the study aims to provide scientific evidence on the benefits of comprehensive, non-pharmacological therapy as a core element in MS treatment.",[64,635,66,636],"Neurorehabilitation","Rehabilitation Exercise",[638,356,391,639,640,641,642,643],"multiple sclerosis","psychotherapy","psychological support","exercise","neurorehabilitation","facilitation and inhibition","2025-11-24",{"date":646,"type":41},"2025-12-01",{"date":648,"type":22},"2025-12-05",{"date":650,"type":22},"2026-12-31",{"name":47,"class":48},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":660,"conditions":661,"keywords":662,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":85},"100577676","left-atrial-posterior-wall-and-mitral-isthmus-pf-ablation-in-non-paroxysmal-af-patients-100577676","NCT06801392","Left Atrial Posterior Wall and Mitral Isthmus PF Ablation in Non-Paroxysmal AF Patients","The Acute Efficacy and Safety of Left Atrial Posterior Wall and Mitral Isthmus Ablation in Patients With Non-Paroxysmal Atrial Fibrillation","Inclusion Criteria:\n\n1. non-paroxysmal atrial fibrillation\n2. an indication for catheter ablation according current guidelines\n3. willingness to sign informed content.\n\nExclusion Criteria:\n\n1. hematological disorders that can be associated with spontaneous hemolysis\n2. chronic kidney disease stage 3 or worse\n3. previous left atrial ablation (either using pulsed-field or radiofrequency energy)",{"count":127,"type":22},"An observational study evaluating efficacy and safety of the Varipulse catheter in pulsed-field ablation of atrial fibrillation",[296],[298,481,663],"varipulse","2025-11-18",{"date":666,"type":41},"2025-11-21",{"date":668,"type":41},"2025-01-01",{"date":670,"type":22},"2025-12",{"name":47,"class":48},{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":676,"acronym":4,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":678,"targetDuration":4,"studyType":23,"phases":680,"briefSummary":681,"conditions":682,"keywords":685,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":85},"100607061","adherence-to-inhaled-therapy---a-globally-overlooked-problem-in-patients-with-chronic-obstructive-pulmonary-disease-and-bronchial-asthma-100607061","NCT07183657","Adherence to Inhaled Therapy - a Globally Overlooked Problem in Patients With Chronic Obstructive Pulmonary Disease and Bronchial Asthma","PATIENTS\n\nInclusion Criteria:\n\n1. signed informed consent,\n2. age ≥ 18 years,\n3. previously diagnosed BA\u002FCOPD meeting GOLD 2024 and GINA 2024 diagnostic criteria,\n4. ability to cooperate,\n5. at least 8 weeks without exacerbation,\n6. use of a particular inhaler for at least 3 months.\n\nExclusion Criteria:\n\n1. pre-terminal\u002Fterminal stage of any disease,\n2. uncooperative patient,\n3. significant limitation of mobility or cognitive functions.\n\nHEALTHCARE PROFESSIONALS\n\nInclusion Criteria:\n\n1. signed informed consent,\n2. completed education in medicine, pharmacy, or nursing,\n3. more than one year of working experience,\n4. care for patients taking inhaled therapy for BA\u002FCOPD.",{"count":679,"type":22},1000,[25],"Comprehensive assessment and interventions to promote adherence to inhaled therapy in patients with bronchial asthma and chronic obstructive pulmonary disease involving health care professionals caring for these patients in different settings and using the Five Steps Assessment tool and artificial intelligence methods and tools.",[683,684],"Chronic Obstructive Pulmonary Disease (COPD)","Bronchial Asthma",[683,686,687,688,689,690],"Intervention","Mobile Application","Bronchial asthma","Adherence","Inhaled therapy","2025-09-25",{"date":693,"type":41},"2025-09-30",{"date":695,"type":41},"2025-06-03",{"date":697,"type":22},"2028-12-31",{"name":47,"class":48},{"id":700,"slug":701,"hasResults":12,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":705,"eligibilityCriteria":706,"healthyVolunteers":94,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":707,"targetDuration":4,"studyType":23,"phases":709,"briefSummary":711,"conditions":712,"keywords":716,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":4},"100598611","phase-2-clacs-using-02-aetoxysklerol-foam-and-70-glucose-for-the-treatment-of-lower-limb-telangiectasias-100598611","NCT07073742","CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias","Randomized, Controlled, Non-Inferiority Trial on the Efficacy of CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias","CLACSO","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Age \\> 18 years.\n3. CEAP classification C1 (telangiectasias only).\n4. Treated area for the study must be ≤ 20x20 cm on the lower limb - thigh.\n\nExclusion Criteria:\n\n1. Reflux in trunk veins or perforators.\n2. Active skin infection at the treatment site.\n3. Presence of reticular veins.\n4. Previous sclerotherapy\u002FCLaCS in the target area.",{"count":708,"type":22},240,[710],"PHASE2","This randomized, controlled, non-inferiority trial aims to compare the efficacy of two sclerosants used in the CLaCS (CryoLaser and CryoSclerotherapy) method for treating telangiectasias and reticular varicose veins. CLaCS is an advanced outpatient procedure that combines Nd\\\\:YAG laser treatment with sclerotherapy to enhance vein closure and cosmetic outcomes while minimizing side effects. The trial will compare the standard 70% glucose sclerosant with a novel 0.2% Aetoxysklerol (polidocanol) foam prepared using the VARIXIO system. Despite widespread use of CLaCS, no head-to-head studies currently exist comparing these two agents. This study aims to determine whether low-concentration Aetoxysklerol foam is non-inferior to 70% glucose in achieving effective telangiectasia elimination.",[713,714,715],"Varicose Veins of Lower Limb","Spider Veins","Reticular Leg Veins",[717,718,719,720],"Telangiectasia","CryoLaser and CryoSclerotherapy","Cosmetic phlebology","AI prediction","2025-07-17",{"date":723,"type":41},"2025-07-18",{"date":725,"type":22},"2025-09-01",{"date":727,"type":22},"2028-09-01",{"name":47,"class":48},""]